Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

California Commercial Lab Certification Recieved

September 22, 2020
RNS Number : 6495Z Renalytix AI PLC 22 September 2020   This announcement contains inside information   Renalytix AI plc ("RenalytixAI", the "Company")   RenalytixAI Receives California Commercial Laboratory Certification   RenalytixAI is now currently licensed to provide KidneyIntelX testing

KidneyIntelX clinical testing launch

September 18, 2020
RNS Number : 4123Z Renalytix AI PLC 18 September 2020     This announcement contains inside information   Renalytix AI plc ("RenalytixAI", the "Company")   RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System   NEW YORK , September 18, 2020 - Renalytix AI

Grant of Purchase Rights and Verici update

September 2, 2020
RNS Number : 7366X Renalytix AI PLC 02 September 2020     Renalytix AI plc ("RenalytixAI", the "Company")   Grant of Purchase Rights under the 2020 Employee Share Purchase Plan and Verici update   NEW YORK , September 2, 2020 - Renalytix AI plc ( LSE: RENX) (NASDAQ: RNLX) announces that on 28

Submission seeking FDA Clearance of KidneyIntelX

August 26, 2020
RNS Number : 1457X Renalytix AI PLC 26 August 2020   Renalytix AI plc ("RenalytixAI", the "Company")   RenalytixAI Files Submission Seeking U.S. FDA Clearance of KidneyIntelX     NEW YORK , August 26, 2020 - Renalytix AI plc ( LSE: RENX) (NASDAQ: RNLX), an artificial intelligence -enabled in vitro

RenalytixAI to Collaborate with AstraZeneca

August 21, 2020
RNS Number : 7551W Renalytix AI PLC 21 August 2020     Renalytix AI plc ("RenalytixAI", the "Company")   RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease   Parties to adopt multi-phase approach to develop precision medicine strategies to optimize

KidneyIntelX in Multi-Center Study

August 3, 2020
RNS Number : 8477U Renalytix AI PLC 03 August 2020     Renalytix AI plc ("RenalytixAI", the "Company")   KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients     Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19   Mount Sinai-Led Study

Total Voting Rights

July 31, 2020
RNS Number : 8003U Renalytix AI PLC 31 July 2020       Renalytix AI plc   (the "Company")    Total Voting Rights   For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following:   As of 31 July 2020 , the Company's issued and fully paid share capital

Over allotment option exercise

July 27, 2020
RNS Number : 0885U Renalytix AI PLC 27 July 2020       Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction   Renalytix AI plc   Over allotment option exercise

Closing of Global Offering and resulting TVR

July 21, 2020
RNS Number : 6782T Renalytix AI PLC 21 July 2020         Renalytix AI plc   Closing of Global Offering and resulting total voting rights   Renalytix AI plc   (LSE : RENX) (NASDAQ: RNLX) (" RenalytixAI " or the " Company "), an artificial intelligence -enabled   in vitro   diagnostics company,

Pricing of Global Offering

July 17, 2020
RNS Number : 3256T Renalytix AI PLC 17 July 2020         This announcement contains inside information   Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction  
Displaying 1 - 10 of 89